These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 19304323)

  • 41. Chronic myelogenous leukemia with the e6a2 BCR-ABL and lacking imatinib response: presentation of two cases.
    Vefring HK; Gruber FX; Wee L; Hovland R; Hjorth-Hansen H; Gedde Dahl T; Meyer P
    Acta Haematol; 2009; 122(1):11-6. PubMed ID: 19641300
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Gata2-L359V impairs primitive and definitive hematopoiesis and blocks cell differentiation in murine chronic myelogenous leukemia model.
    Fu YK; Tan Y; Wu B; Dai YT; Xu XG; Pan MM; Chen ZW; Qiao N; Wu J; Jiang L; Lu J; Chen B; Rein A; Izraeli S; Sun XJ; Huang JY; Huang QH; Chen Z; Chen SJ
    Cell Death Dis; 2021 Jun; 12(6):568. PubMed ID: 34078881
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Trends in survival after diagnosis with hematologic malignancy in adolescence or young adulthood in the United States, 1981-2005.
    Pulte D; Gondos A; Brenner H
    Cancer; 2009 Nov; 115(21):4973-9. PubMed ID: 19705347
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Identification of acquired mutations by whole-genome sequencing in GATA-2 deficiency evolving into myelodysplasia and acute leukemia.
    Fujiwara T; Fukuhara N; Funayama R; Nariai N; Kamata M; Nagashima T; Kojima K; Onishi Y; Sasahara Y; Ishizawa K; Nagasaki M; Nakayama K; Harigae H
    Ann Hematol; 2014 Sep; 93(9):1515-22. PubMed ID: 24782121
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The allometry of chronic myeloid leukemia.
    Pacheco JM; Traulsen A; Dingli D
    J Theor Biol; 2009 Aug; 259(3):635-40. PubMed ID: 19362566
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Master regulatory GATA transcription factors: mechanistic principles and emerging links to hematologic malignancies.
    Bresnick EH; Katsumura KR; Lee HY; Johnson KD; Perkins AS
    Nucleic Acids Res; 2012 Jul; 40(13):5819-31. PubMed ID: 22492510
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [RT-PCR use for the diagnostic of chronic myeloid leukaemia].
    Menif S; El Borgi W; Jeddi R; Belakhal R; Elloumi M; Laatiri A; Meddeb B; Dellagi K
    Arch Inst Pasteur Tunis; 2006; 83(1-4):35-9. PubMed ID: 19388595
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Molecular diagnosis of myeloproliferative neoplasms.
    Patnaik MM; Tefferi A
    Expert Rev Mol Diagn; 2009 Jul; 9(5):481-92. PubMed ID: 19580432
    [TBL] [Abstract][Full Text] [Related]  

  • 49. GATA factor mutations in hematologic disease.
    Crispino JD; Horwitz MS
    Blood; 2017 Apr; 129(15):2103-2110. PubMed ID: 28179280
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Correlation of quantification of major bcr-abl mRNA between TMA (transcription mediated amplification) method and real-time quantitative PCR].
    Yagasaki F; Niwa T; Abe A; Ishikawa M; Kato C; Ogura K; Sasaki H; Kyo T; Jinnai I; Bessyo M; Miyamura K
    Rinsho Ketsueki; 2009 Jun; 50(6):481-7. PubMed ID: 19571508
    [TBL] [Abstract][Full Text] [Related]  

  • 51. DNMT3A mutations in myeloproliferative neoplasms.
    Stegelmann F; Bullinger L; Schlenk RF; Paschka P; Griesshammer M; Blersch C; Kuhn S; Schauer S; Döhner H; Döhner K
    Leukemia; 2011 Jul; 25(7):1217-9. PubMed ID: 21537334
    [No Abstract]   [Full Text] [Related]  

  • 52. Hematological malignancies: role of miRNAs and their in silico aspects.
    Omer A; Yadav NK; Singh P; Singh RK
    Expert Rev Anticancer Ther; 2013 Sep; 13(9):1121-33. PubMed ID: 24053209
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Combination therapies against chronic myeloid leukemia: short-term versus long-term strategies.
    Komarova NL; Wodarz D
    Cancer Res; 2009 Jun; 69(11):4904-10. PubMed ID: 19458080
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Analysis of the quality of reporting of randomized controlled trials in acute and chronic myeloid leukemia, and myelodysplastic syndromes as governed by the CONSORT statement.
    Ziogas DC; Zintzaras E
    Ann Epidemiol; 2009 Jul; 19(7):494-500. PubMed ID: 19523596
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Prolonged chronic phase in chronic myelogenous leukemia after homoharringtonine therapy.
    Li YF; Deng ZK; Xuan HB; Zhu JB; Ding BH; Liu XN; Chen BA
    Chin Med J (Engl); 2009 Jun; 122(12):1413-7. PubMed ID: 19567163
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Myeloid malignancies with somatic
    Alfayez M; Wang SA; Bannon SA; Kontoyiannis DP; Kornblau SM; Orange JS; Mace EM; DiNardo CD
    Leuk Lymphoma; 2019 Aug; 60(8):2025-2033. PubMed ID: 30648453
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Molecular basis of hematological malignancies].
    Kitamura T; Inoue D; Nakahara F; Okochi N; Kato N; Togami K; Uchida T; Kagiyama Y; Kawabata KC; Nagase R; Horikawa S; Hayashi K; Saika M; Izawa K; Oki T; Chiba S; Harada Y; Harada H; Kitaura J
    Rinsho Ketsueki; 2014 Oct; 55(10):1715-23. PubMed ID: 25297732
    [No Abstract]   [Full Text] [Related]  

  • 58. GATA2 mutations in myeloid malignancies: Two zinc fingers in many pies.
    Leubolt G; Redondo Monte E; Greif PA
    IUBMB Life; 2020 Jan; 72(1):151-158. PubMed ID: 31785092
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Expression of GATA-1 and GATA-2 in the bone marrow of patients with Monge's disease].
    Li JP; Jia NY; Li ZQ; Wang HX; Su J; Li YL; Li XM
    Zhonghua Xue Ye Xue Za Zhi; 2007 Aug; 28(8):537-40. PubMed ID: 18078130
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Bilateral hypopyon as the presenting feature of chronic myeloid leukemia.
    Sudharshan S; Kumari A; Biswas J
    Ocul Immunol Inflamm; 2008; 16(5):244-6. PubMed ID: 19065423
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.